Market research
MRUS Merus BV
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 97
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0011606264
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 97
- Dividend yield
- Not available
- Beta
- 1.06
About
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MRUS discussion.
5 years, 4 months ago
Merus N.V is currently in a long term uptrend where the price is trading 3.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.1.
Merus N.V's total revenue rose by 20.0% to $9M since the same quarter in the previous year.
Its net income has dropped by 7.0% to $-28M since the same quarter in the previous year.
Finally, its free cash flow fell by 32.9% to $-25M since the same quarter in the previous year.
Based on the above factors, Merus N.V gets an overall score of 3/5.